Breast Cancer ResearchThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9

438 records returned

Rah, rah, ROS: metabolic changes caused by loss of adhesion induce cell deathEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The high rate of glucose utilization by cancer cells has been well characterized. Recent data suggest that when normal mammary epithelial cells are cultured under nonadherent conditions, glucose consumption decreases, ATP levels fall, and concentrations of reactive oxygen species rise. The rise in reactive oxygen species causes death of nonadherent cells, which can be suppressed with antioxidants. Nonadherent ErbB2-transformed mammary epithelial cells maintain glucose transport and antioxidant production; however, antioxidants appear to enhance anchorage-independent growth. These findings integrate aspects of glucose metab...
Source: Breast Cancer Research - November 18, 2009 Category: Cancer & Oncology Authors: Christian YoungSteven Anderson Source Type: journals

Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community settingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The marked increase in the 1990s in the use of adjuvant therapy for DCIS patients treated with BCS in the community setting only partially explains the 50% decline in risk of recurrence risk. Changes in pathology factors have likely also contributed to this decline. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 18, 2009 Category: Cancer & Oncology Authors: Laurel HabelNinah AchacosoReina HaqueLarissa NekhlyudovSuzanne FletcherStuart SchnittLaura CollinsAnn GeigerBalaram PuligandlaLuana ActonCharles Quesenberry Source Type: journals

Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The expression of pFAK, HIF-1 alpha, VEGF and VEGFR2 in CTCs of patients with metastatic breast cancer could explain the metastatic potential of these cells and may provide a therapeutic target for their elimination. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 17, 2009 Category: Cancer & Oncology Authors: Galatea KallergiHarris MarkomanolakiVicky GiannoukarakiMaria PapadakiAreti StratiEvi LianidouVassilis GeorgouliasDimitris MavroudisSophia Agelaki Source Type: journals

Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Ku proteins in interaction with AP-2 (alpha and gamma) contribute to increased ERBB2 mRNA and protein levels in breast cancer cells. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 11, 2009 Category: Cancer & Oncology Authors: Gregory NolensJean-Christophe PignonBenjamin KoopmanschBenaissa ElmoualijWilly ZorziEdwin De PauwRosita Winkler Source Type: journals

Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our data demonstrate that the invasive, mesenchymal CD44posCD24neg phenotype is under dynamic control in breast cancer cell lines both in vivo and in vitro. Furthermore, our observations suggest that targeted therapy against CD44posCD24neg tumor cells may have limited success in preventing primary tumor metastasis unless Activin/Nodal signaling is arrested. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 11, 2009 Category: Cancer & Oncology Authors: Matthew MeyerJodie FlemingMustapha AliMitchell PeseskyErika GinsburgBarbara Vonderhaar Source Type: journals

Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our data constitutes the first report of direct involvement of 5-HT in human breast cancer. Increased 5-HT biosynthetic capacity accompanied by multiple changes in 5-HT receptor expression and signaling favor malignant progression of human breast cancer cells (e.g., stimulated proliferation, inappropriate cell survival). This occurs through uncoupling of serotonin from the homeostatic regulatory mechanisms of the normal mammary epithelium. The findings open a new avenue for identification of diagnostic and prognostic markers, and valuable new therapeutic targets for managing breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 10, 2009 Category: Cancer & Oncology Authors: Vaibhav PaiAaron MarshallLaura HernandezArthur BuckleyNelson Horseman Source Type: journals

Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We present a novel technique for estimating breast density based on 3D T1-weighted magnetic resonance imaging (MRI) and evaluate its performance, including for breast cancer risk prediction, relative to two standard mammographic density-estimation methods. Methods: The analyses were based on MRI (n = 655) and mammography (n = 607) images obtained in the course of the UK multicentre magnetic resonance imaging breast screening (MARIBS) breast-screening study of asymptomatic women aged 31 - 49 years who were at high genetic risk of breast cancer. The MRI percent and absolute dense volumes were estimated using our novel algori...
Source: Breast Cancer Research - November 10, 2009 Category: Cancer & Oncology Authors: Deborah ThompsonMartin LeachGek Kwan-LimSimon GaytherSusan RamusIqbal WarsiFiona LennardMichael KhazenEmilie BryantSadie ReedCaroline BoggisD EvansRosalind EelesDouglas EastonRuth Warren Source Type: journals

Epithelial to Mesenchymal Transition and Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Epithelial-mesenchymal plasticity in breast carcinoma encompasses the phenotypic spectrum whereby epithelial carcinoma cells within a primary tumor acquire mesenchymal features and re-epithelialize to form a cohesive secondary mass at a metastatic site. Understanding of the underlying molecular and cellular processes in breast cancer is advancing- they are transcriptionally and epigenetically regulated, can be monitored using an increasing array of marker proteins, and result in characteristic changes in cell behavior. Such plasticity has implications in progression of breast carcinoma to metastasis, and will likely influe...
Source: Breast Cancer Research - November 9, 2009 Category: Cancer & Oncology Authors: Eva Tomaskovic-CrookErik ThompsonJean Paul Thiery Source Type: journals

From normal cell types to malignant phenotypesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The phenotypic diversity of breast cancer has been proposed to result from different target cell types undergoing oncogenic transformation and giving rise to cancer stem cells (CSCs). Global gene expression profiling revealed distinct molecular phenotypes and some of these signatures were held to reflect the cell of origin with the basal carcinomas arising from basal/progenitor cells. Recent work challenges this view by providing evidence that luminal precursor cells are involved in the pathogenesis of basal breast cancers and made new links between normal cell populations and molecular tumor phenotypes. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 9, 2009 Category: Cancer & Oncology Authors: Özden Yalcin-OzuysalCathrin Brisken Source Type: journals

A selective eradication of human non-hereditary breast cancer cells by phenanthridine derived polyADP-ribose polymerase inhibitorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These results outline a new therapeutic approach for a selective eradication of abundant non-hereditary human breast cancers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 5, 2009 Category: Cancer & Oncology Authors: Dana Inbar-RozensalAsher CastielLeonid VisochekDavid CastelFrancoise DantzerShai IzraeliMalka Cohen-Armon Source Type: journals

Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Together the data suggest that Hes-6 is a potential oncogene over expressed in breast cancer, with a tumor promoting and proliferative function. Furthermore, Hes-6 is a novel estrogen regulated gene in breast cancer cells. An understanding of the role and regulation of Hes-6 could provide insights into estrogen signaling and endocrine resistance in breast cancer and, hence, be important for the development of novel anticancer drugs. (Source: Breast Cancer Research)
Source: Breast Cancer Research - November 5, 2009 Category: Cancer & Oncology Authors: Johan HartmanEric LamJan-Ake GustafssonAnders Strom Source Type: journals

Androgens and the breastEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Androgens have important physiological effects in women while at the same time they may be implicated in breast cancer pathologies. However data on the effects of androgens on mammary epithelial proliferation and/or breast cancer incidence are not in full agreement.We performed a literature review evaluating current clinical, genetic and epidemiological data regarding the role of androgens in mammary growth and neoplasia.Epidemiologic studies appear significant methodological limitations and thus provide inconclusive results. The study of molecular defects involving androgenic pathways in breast cancer is still in its infa...
Source: Breast Cancer Research - October 30, 2009 Category: Cancer & Oncology Authors: Constantine DimitrakakisCarolyn Bondy Source Type: journals

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991. (Source: Breast Cancer Research)
Source: Breast Cancer Research - October 29, 2009 Category: Cancer & Oncology Authors: Richard FinnJudy DeringDylan ConklinOndrej KalousDavid CohenAmrita DesaiCharles GintherMohammad AtefiIsan ChenCamilla FowstGerret LosDennis Slamon Source Type: journals

Update on the use of aromatase inhibitors in early breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aromatase inhibitors are currently included in the 'optimal' management of early-stage breast cancer. Uncertainty remains, however, as to the most appropriate treatment strategy, particularly for newly diagnosed women as they seek to trade off the cost, toxicities and efficacy of the treatment options. Recent publications provide conflicting advice on the role of aromatase inhibitors in the treatment of postmenopausal patients with early-stage hormone receptor-positive breast cancer. This review provides updates on the clinical trials of aromatase inhibitors in early breast cancer and tries to provide practical clinical gu...
Source: Breast Cancer Research - October 28, 2009 Category: Cancer & Oncology Authors: Georgios KesisisAndreas MakrisDavid Miles Source Type: journals

Key signalling nodes in mammary gland development and cancer: MycEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Myc has been intensely studied since its discovery more than 25 years ago. Insight has been gained into Myc's function in normal physiology, where its role appears to be organ specific, and in cancer where many mechanisms contribute to aberrant Myc expression. Numerous signals and pathways converge on Myc, which in turn acts on a continuously growing number of identified targets, via transcriptional and nontranscriptional mechanisms. This review will concentrate on Myc as a signaling mediator in the mammary gland, discussing its regulation and function during normal development, as well as its activation and roles in breas...
Source: Breast Cancer Research - October 14, 2009 Category: Cancer & Oncology Authors: Nancy HynesTina Stoelzle Source Type: journals

Notch versus the Proteasome: What is the Target of Gamma-secretase Inhibitor-I?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gamma-secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is yet unclear. Han et al. investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasome inhibition independent of Notch activity. Currently, gamma-secretase inhibitors in clinical trials are structurally distinct from Z-LeuLeuNleu-CHO. Their effects on the proteasome are yet to be determined. However, findings from Han et al. pose two critical questions: Is the level of proteasomal activity in breast tumors the driving ...
Source: Breast Cancer Research - October 14, 2009 Category: Cancer & Oncology Authors: Anthony ClementzClodia Osipo Source Type: journals

Key signaling nodes in mammary gland development and breast cancer: MycEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Myc has been intensely studied since its discovery more than 25 years ago. Insight has been gained into Myc's function in normal physiology, where its role appears to be organ specific, and in cancer where many mechanisms contribute to aberrant Myc expression. Numerous signals and pathways converge on Myc, which in turn acts on a continuously growing number of identified targets, via transcriptional and non-transcriptional mechanisms. This review will concentrate on Myc as a signaling mediator in the mammary gland, discussing its regulation and function during normal development, as well as its activation and roles in brea...
Source: Breast Cancer Research - October 14, 2009 Category: Cancer & Oncology Authors: Nancy HynesTina Stoelzle Source Type: journals

Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis. The results also suggest that lymphatic and hematogeneous metastases are genetically distinct that may involve different mechanisms. If true, these results suggest that metastatic disease, like primary breast cancer, may be multiple diseases and that stratification of late stage patients may therefore be required to fully understand breast cancer progression and metastasis. (Source: Breast Cancer Research)
Source: Breast Cancer Research - October 12, 2009 Category: Cancer & Oncology Authors: Szu-Min HsiehMaxime LookAnieta SieuwertsJohn FoekensKent Hunter Source Type: journals

BU-32: a novel proteasome inhibitor for breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: We have shown that BU-32 is effective in cultured breast cancer cells and in breast cancer xenografts. The results suggest its potential benefit in breast cancer treatment. (Source: Breast Cancer Research)
Source: Breast Cancer Research - October 11, 2009 Category: Cancer & Oncology Authors: Joseph AgyinBindu SanthammaHareesh NairSudipa RoyRajeshwar Tekmal Source Type: journals

Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison to status of bone marrow-disseminated tumor cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In breast cancer, CTCs/DTCs may serve as independent adverse prognostic variables, to monitor the course of the disease and to predict response or failure to cancer therapy. Most of the techniques to enumerate disseminated tumor cells (DTCs) in the bone marrow, or circulating tumor cells (CTCs) in the bloodstream of breast cancer patients, rely on a combination of an enrichment and a detection step. A novel, RT-PCR method, the AdnaTest BreastCancer kit, was developed for the enrichment of CTCs from peripheral blood of breast cancer patients followed by identification of CTC-associated marker transcripts by reverse transcri...
Source: Breast Cancer Research - October 8, 2009 Category: Cancer & Oncology Authors: Manfred SchmittJohn Foekens Source Type: journals

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Repeated iv administration of AS1402 was well tolerated, with a maximum tolerated dose (MTD) exceeding 16 mg/kg, the highest dose administered in this study. The half-life and exposure of AS1402 were such that weekly dosing could achieve plasma concentrations corresponding to the maximal ADCC activity observed in vitro. A phase II study is ongoing to evaluate the clinical activity of AS1402 in patients with advanced breast cancer.Trial registration: ClinicalTrials.gov Identifier: NCT00096057. (Source: Breast Cancer Research)
Source: Breast Cancer Research - October 6, 2009 Category: Cancer & Oncology Authors: Mark PegramVirginia BorgesNuhad IbrahimJyotsna FuloriaCharles ShapiroSusan PerezKaren WangFranziska Schaedeli StarkNigel Courtenay Luck Source Type: journals

Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland developmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Seven classes of mitogen-activated protein kinase (MAPK) intracellular signalling cascades exist, four of which are implicated in breast disease and function in mammary epithelial cells. These are the extracellular regulated kinase (ERK)1/2 pathway, the ERK5 pathway, the p38 pathway and the c-Jun N-terminal kinase (JNK) pathway. In some forms of human breast cancer and in many experimental models of breast cancer progression, signalling through the ERK1/2 pathway, in particular, has been implicated as being important. We review the influence of ERK1/2 activity on the organised three-dimensional association of mammary epith...
Source: Breast Cancer Research - September 28, 2009 Category: Cancer & Oncology Authors: Jackie WhyteOrla berginalessandro bianchisara mc nallyfinian martin Source Type: journals

MAP kinase signaling in experimental models of breast cancer progression and in mammary gland developmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Three MAPK (Mitogen Activated Protein Kinase) intracellular signalling cascades, the ERK (Extra-cellular-Regulated-Kinase) pathway, the p38 pathway and the JNK (c-Jun N-terminal Kinase) pathway function in mammalian cells. In some forms of human breast cancer and in many experimental models of breast cancer progression, signalling through the ERK pathway, in particular, has been implicated as being important. We review the influence of ERK activity on organised association of mammary epithelial cells in 3-D, and in models of breast cancer cell invasion. We assess the importance of EGFR family signalling through ERK in mode...
Source: Breast Cancer Research - September 28, 2009 Category: Cancer & Oncology Authors: Jackie WhyteOrla berginalessandro bianchisara mc nallyfinian martin Source Type: journals

Development of "synthetic lethal" strategies to target BRCA1-deficient breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Recent clinical trials demonstrating the efficacy of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors for the treatment of BRCA1-deficient breast cancer have provided support for the "synthetic lethal" concept of targeted cancer therapeutics. In this issue, Puppe et al.1, provide further preclinical validation of this concept by demonstrating that BRCA1-deficient mouse mammary tumor cells are selectively sensitive to an inhibitor of the polycomb gene EZH2. The development of polycomb gene inhibitors may provide a novel approach to selectively exploit the molecular alterations in BRCA1-deficient breast ...
Source: Breast Cancer Research - September 22, 2009 Category: Cancer & Oncology Authors: Max Wicha Source Type: journals

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
IntroductionThe origin and clinical relevance of circulating cell-free tumor DNA in blood of cancer patients is still unclear. Here we investigated whether the detection of this DNA is related to bone marrow (BM) micrometastasis and tumor recurrence in breast cancer patients. Methods: BM aspirates of 81 primary breast cancer patients were analyzed for the presence of disseminated tumor cells (DTC) by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3. PCR-based fluorescence microsatellite analysis was performed for detection of loss of heterozygosity (LOH) at 6 polymorphic markers using cell-free serum DNA. Th...
Source: Breast Cancer Research - September 20, 2009 Category: Cancer & Oncology Authors: Heidi SchwarzenbachKlaus PantelBirthe KemperCord BeegerFriedrich OtterbachRainer KimmigSabine Kasimir-Bauer Source Type: journals

The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
IntroductionPrevious studies indicate that overexpression of the membrane-associated mucin MUC4 is potently anti-adhesive to cultured tumor cells, and suppresses cellular apoptotic response to a variety of insults. Such observations raise the possibility that MUC4 expression could contribute to tumor progression or metastasis, but the potential involvement of MUC4 in breast cancer has not been rigorously assessed. The present study aimed to investigate the expression of the membrane mucin MUC4 in normal breast tissue, primary breast tumors and lymph node metastases, and to evaluate the role of MUC4 in promoting the maligna...
Source: Breast Cancer Research - September 16, 2009 Category: Cancer & Oncology Authors: Heather WorkmanJamie MillerEllen IngallaRouminder KaurDiane YamamotoLaurel BeckettLawrence YoungRobert CardiffAlexander BorowskyKermit CarrawayColleen SweeneyKermit Carraway Source Type: journals

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
IntroductionReliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable breast cancer to test for associations with pathological complete response (pCR) and disease-free survival (DFS). Particularly, we evaluated if interactions between hormone receptor (HR) and HER2 expression might lead to a different clinical behavior of HR+/HER2+ co-expressing and HR+/HER2- tumors and whether s...
Source: Breast Cancer Research - September 15, 2009 Category: Cancer & Oncology Authors: Silvia Darb-EsfahaniSibylle LoiblBerit MullerMarc RollerCarsten DenkertMartina KomorKarsten SchlunsJens-Uwe BlohmerJan BudcziesBernd GerberAurelia NoskeAndreas du BoisWilko WeichertChristian JackischManfred DietelKlaus RichterManfred KaufmannGunter von Mi Source Type: journals

Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
IntroductionThe steroid receptor RNA activator is a functional RNA suspected to participate in the mechanisms underlying breast tumor progression. This RNA is also able to encode for a protein, SRAP, whose exact function remains to be determined. Our aim was to assess, in a large breast cancer cohort, whether levels of this protein could be associated with outcome or established clinical parameters. Methods: Following antibody validation, SRAP expression was assessed by tissue-microarray (TMA) analysis of 372 breast tumors. Clinical follow-up and parameters such as steroid receptor and node status were available for all th...
Source: Breast Cancer Research - September 8, 2009 Category: Cancer & Oncology Authors: Yi YanGeorge SklirisCarla PennerShilpa Chooniedass-KothariCharlton CooperZoann NugentAnne BlanchardPeter WatsonYvonne MyalLeigh MurphyEtienne Leygue Source Type: journals

Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our studies identify an essential function for FAK in mediating the interaction between beta3 integrin and TBR-II, and thus in facilitating the oncogenic conversion of TGF-beta required for mammary tumor metastasis. Furthermore, this study establishes chemotherapeutic targeting of FAK as an effective, two-pronged approach in preventing tumor progression by both decreasing innate immune cell infiltration, as well as by inhibiting early TGF-beta-dependent metastasis. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 8, 2009 Category: Cancer & Oncology Authors: Michael WendtWilliam Schiemann Source Type: journals

An intra-ductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The intra-ductal HIM transplantation model provides an invaluable tool that mimics human breast heterogeneity at the non-invasive stages and allows the study of the distinct molecular and cellular mechanisms of breast cancer progression. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 6, 2009 Category: Cancer & Oncology Authors: Fariba BehbodFrances KittrellHeather LaMarcaDavid EdwardsSofia KerbawyJessica HeestandEvelin YoungPurna MukhopadhyayHung-Wen YehD Craig AllredMin HuKornelia PolyakJeffrey RosenDaniel Medina Source Type: journals

Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: To our knowledge, the results reported here are the first measurements of the timescale and characteristics of progression from in situ neoplasia to invasive carcinoma and provide image-based evidence that DCIS may be a non-obligate precursor lesion with highly variable outcomes. In addition, this study represents a first step towards developing methods of image acquisition for identifying radiological characteristics that might predict which in situ neoplasias will become invasive cancers and which are unlikely to progress. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 3, 2009 Category: Cancer & Oncology Authors: Sanaz JansenSuzanne ConzenXiaobing FanErica MarkiewiczGillian NewsteadGregory Karczmar Source Type: journals

Correction: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No description available (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 1, 2009 Category: Cancer & Oncology Source Type: journals

Physical activity and breast cancer survivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Physical activity improves quality of life after a breast cancer diagnosis, and a beneficial effect on survival would be particularly welcome. Four observational studies have now reported decreased total mortality among physically active women with breast cancer; the two largest have also reported decreased breast cancer specific mortality. The estrogen pathway and the insulin pathway are two potential mechanisms by which physical activity could affect breast cancer survival. Randomized trials are ongoing but trials of lifestyle factors are notoriously challenging to perform. Women with breast cancer have little to lose an...
Source: Breast Cancer Research - August 31, 2009 Category: Cancer & Oncology Authors: Adeyemi OgunleyeMichelle Holmes Source Type: journals

Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition CohortEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
IntroductionVitamin D status measured during adulthood has been inversely associated with breast cancer risk in some, but not all studies. Vitamin D has been hypothesized to prevent breast cancer through genomic and non-genomic actions in cell-cycle regulation. Methods: A subset (n=21,965) of female participants from the prospective Cancer Prevention Study-II (CPS-II) Nutrition Cohort provided a blood sample from 1998-2001 and were followed through 2005. We measured serum 25-hydroxyvitamin D (25(OH)D) in 516 verified incident cases and 516 controls, matched on birth date (+/- 6 months), date of blood draw (+/- 6 months) an...
Source: Breast Cancer Research - August 27, 2009 Category: Cancer & Oncology Authors: Marjorie McCulloughVictoria StevensRoshni PatelEric JacobsElizabeth BainRonald HorstSusan GapsturMichael ThunEugenia Calle Source Type: journals

Recent Advances in Systemic Therapy for Breast Cancer: New technologies for a new EraEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The last decade has brought enormous advance in the way we manage breast cancer patients with systemic therapies. An explosion in our understanding of the molecular pathogenesis of breast cancer, a harnessing of powerful new diagnostic technologies, and the culmination of a series of pivotal randomised trials of cytotoxic and novel targeted therapies has seen significant improvements in outcome for patients with both early and advanced disease. This series of articles by leading clinical researchers explore these advances in different areas of breast cancer management. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 27, 2009 Category: Cancer & Oncology Authors: Paul Ellis Source Type: journals

When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The anti-HER2 agent trastuzumab has improved outcomes for breast cancer patients with HER2-overexpressing tumours. However, systemic treatment for patients with HER2-negative disease is still limited to endocrine and cytotoxic therapies. The increasing use of the anthracyclines and taxanes in early stage disease has reduced the available therapeutic options for patients with relapsed disease, and options are further limited for patients with triple-negative tumours, who typically have a poor prognosis. The novel agents bevacizumab and ixabepilone have recently been approved for metastatic breast cancer and numerous other a...
Source: Breast Cancer Research - August 27, 2009 Category: Cancer & Oncology Authors: David Miles Source Type: journals

Resident macrophages influence stem cell activity in the mammary glandEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our data reveal a key role for mammary gland macrophages in supporting stem/progenitor cell function and suggest that MaSCs require macrophage-derived factors to be fully functional. Macrophages may therefore constitute part of the mammary stem cell niche. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 25, 2009 Category: Cancer & Oncology Authors: David GyorkiMarie-Liesse Asselin-LabatNico van RooijenGeoffrey LindemanJane Visvader Source Type: journals

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin AEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: We demonstrate by specific knock-down experiments that Ezh2 overexpression is functionally relevant in BRCA1-deficient breast cancer cells. The effectiveness of a small molecule inhibitor indicates that EZH2 is a druggable target. The overexpression of EZH2 in all basal-like breast cancers warrants further investigation of the potential for targeting the genetic make-up of this particular breast cancer type. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 25, 2009 Category: Cancer & Oncology Authors: Julian PuppeRinske DrostXiaoling LiuSimon JoosseBastiaan EversPaulien Cornelissen-SteijgerPetra NederlofQiang YuJos JonkersMaarten van LohuizenAlexandra Pietersen Source Type: journals

Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These data suggest that p190B haploinsufficiency in the epithelium inhibits MMTV-Neu tumor initiation. Furthermore, p190B deficiency in the vasculature is responsible, in part, for the inhibition of MMTV-Neu tumor progression. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 23, 2009 Category: Cancer & Oncology Authors: Brandy Heckman-StoddardTracy Vargo-GogolaPeter McHenryVivian JiangMatthew HerrickSusan HilsenbeckJeffrey SettlemanJeffrey Rosen Source Type: journals

It's all in the details: methods in breast development and cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The inaugural European Network for Breast Development and Cancer (ENBDC) meeting on "Methods in Mammary Gland Development and Cancer" was held in Weggis/Switzerland last April. The goal was to discuss the details of techniques used to study mammary gland biology and tumorigenesis. Highlights of this meeting included the use of 4-colour fluorescence for protein co-localisation in tissue microarrays, genome analysis at single cell resolution, technical issues in the isolation of normal and tumour stem cells, and the use of mouse models and mammary gland transplantations to elucidate gene function in mammary development and t...
Source: Breast Cancer Research - August 13, 2009 Category: Cancer & Oncology Authors: Mohamed Bentires-AljRobert ClarkeJos JonkersMatthew SmalleyTorsten Stein Source Type: journals

Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The combination of in vitro functional studies with the analysis of gene expression in clinical breast cancer samples indicates that three functionally inter-connected genes, Fau, Bcl-G and MELK, are crucially important in breast cancer and identify them as attractive targets for improvements in breast cancer risk prediction, prognosis and therapy. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 10, 2009 Category: Cancer & Oncology Authors: Mark PickardAndrew GreenIan EllisCarlos CaldasVanessa HedgeMirna Mourtada-MaarabouniGwyn Williams Source Type: journals

MicroRNA expression profiling of male breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our results suggest that specific miRNAs may be directly involved in male breast cancer development and that they may represent a novel diagnostic tool in the characterization of specific cancer gene targets. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 9, 2009 Category: Cancer & Oncology Authors: Matteo FassanRaffaele BaffaJuan PalazzoJoshua LloydMarco CrosariolChang-Gong LiuStefano VoliniaHannes AlderMassimo RuggeCarlo CroceAnne Rosenberg Source Type: journals

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by reverse-transcriptase polymerase chain reaction and comparison to status of bone marrow disseminated cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: (1) Due to the weak concordance between CTC and DTC the clinical relevance may be different. (2) The biology of the primary tumor seems to direct the spread of CTC. (3) Since the expression profile between CTC and the primary tumor differs, the consequence for the selection of adjuvant treatment has to be evaluated. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 9, 2009 Category: Cancer & Oncology Authors: Tanja FehmOliver HoffmannBahriye AktasSven BeckerErich SolomayerDiethelm WallwienerRainer KimmigSabine Kasimir-Bauer Source Type: journals

The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibitionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: We conclude that the cytotoxicity of Z-LLNle-CHO in breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. (Source: Breast Cancer Research)
Source: Breast Cancer Research - August 5, 2009 Category: Cancer & Oncology Authors: Jianxun HanIvy MaMichael HendzelJoan Allalunis-Turner Source Type: journals

Is there more to Wnt signalling than beta-catenin stabilisation in breast cancer?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Increased Wnt signalling has been implicated in the aetiology of many different human cancers, including breast cancers. In most cases, Wnt signalling is thought to drive tumourigenesis through the stabilisation of cytosolic β-catenin and the subsequent changes in the expression of T-cell factor (TCF)-dependent genes. However, this is not necessarily the only mechanism, as Wnt proteins can signal through a number of different intracellular signalling pathways. The ongoing work from Nancy Hynes' laboratory continues to highlight this latter possibility. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 29, 2009 Category: Cancer & Oncology Authors: Giovanna ColluOlivier MeuretteKeith Brennan Source Type: journals

Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The data clearly has important clinical implications for patients diagnosed with metastatic breast cancer, especially with regards to the prognosis and treatment options. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 29, 2009 Category: Cancer & Oncology Authors: Lopamudra RoyLatha PathangeyTeresa TinderJorge SchettiniHelen GruberPinku Mukherjee Source Type: journals

Tumour aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
IntroductionTo determine whether the levels of expression of 17 candidate genes were associated with loco-regional control after breast conserving treatments of early-stage breast cancers in young, premenopausal women. Methods: Gene expression was measured using RT-PCR in the breast tumors of a series of 53 young ( (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 27, 2009 Category: Cancer & Oncology Authors: Marc BolletAlexia SavignoniLeanne De KoningCarine Tran PerennouCatherine BarbarouxArmelle DegeorgesBrigitte Sigal-ZafraniGenevieve AlmouzniPaul CottuRemy SalmonNicolas ServantAlain FourquetPatricia de Cremoux Source Type: journals

An integration of complementary strategies for gene expression analysis to reveal novel therapeutic opportunities for breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Genomic analyses can be used to dissect the heterogeneity of breast cancer. We use an integrated analysis of breast cancer that combines independent methods of genomic analyses to highlight the complexity of signaling pathways underlying different breast cancer phenotypes, and to identify optimal therapeutic opportunities. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 27, 2009 Category: Cancer & Oncology Authors: Andrea BildJoel ParkerAdam GustafsonChaitanya AcharyaKatherine HoadleyCarey AndersP Kelly MarcomLisa CareyAnil PottiJoseph NevinsCharles Perou Source Type: journals

TGFb and mutant-p53 Conspire to Induce Metastasis by Antagonizing p63: A (ternary) Complex Affair.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
How and when a tumor acquires metastatic properties remain largely unknown. Recent work has uncovered an intricate new mechanism through which transforming growth factor-beta (TGFβ) acts in concert with oncogenic Ras to antagonize p63-metastasis protective function. p63 inhibition requires the combined action of Ras-activated mutant p53 and TGFβ-induced Smads. Mechanistically, it involves the formation of a p63-Smads-mutant p53 ternary complex. Remarkably, just two of the key downstream targets of p63 turn out to be sufficient as a prognostic tool for breast cancer metastasis. Moreover, the molecular mechanism of this in...
Source: Breast Cancer Research - July 26, 2009 Category: Cancer & Oncology Authors: Jean-Christophe MarineGeert Berx Source Type: journals

Construction of a MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for gene therapy of breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: This construct may allow multimodal therapy, combining virotherapy with radioiodine therapy to be developed as a novel treatment for breast and other MUC1 overexpressing cancers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 26, 2009 Category: Cancer & Oncology Authors: Miguel TrujilloMichael OnealJulia DavydovaElizabeth BergertMasato YamamotoJohn Morris Source Type: journals